Vasoactive intestinal peptide and bipolar affective illness. Evidence for an effect of lithium

Wade H. Berrettini, John I. Nurnberger, Peter Hotvedt, Susan Simmons-Alling, Elliot S. Gershon

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

In an attempt to evaluate the role of VIP in affective disorder, measurements of lymphocyte VIP receptors, and plasma and CSF VIP levels were made in unmedicated and lithium-treated euthymic bipolars and controls. Lithium decreased plasma (P=0.01) and CSF (P=0.05) VIP levels and increased the affinity (decreased the KD) of the VIP lymphocyte receptor (P<0.01). This effect may be relevant to the psychotropic action of lithium in manic-depressive illness.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalJournal of Affective Disorders
Volume8
Issue number1
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Keywords

  • Bipolar affective illness - Lithium - Vasoactive intestinal peptide (VIP)

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Vasoactive intestinal peptide and bipolar affective illness. Evidence for an effect of lithium'. Together they form a unique fingerprint.

  • Cite this